A longitudinal analysis of immune escapes from HLA-B*13-restricted T-cell responses at early stage of CRF01_AE subtype HIV-1 infection and implications for vaccine design

Table 1 Clinical characteristics of CRF01_AE subtype HIV-1-infected individuals

PID	HLA class I			Early			3 months^d			1 year			Set point^a
PID	HLA-A	HLA-B	HLA-C	dpi	CD4 (cells/μL)	VL (copies/mL)	dpi	CD4 (cells/μL)	VL (copies/mL)	dpi	CD4 (cells/μL)	VL (copies/mL)	Set point^a
320829	A24 A24	B13 B15	C03 C03	51^b	531	5.42	120^b	653	5.44	352^b	616	5.43	5.44
320018	A02 A30	B13 B13	C06 C07	34^b	464	5.33	58^bc	293	5.18	330^bc	281	5.08	5.08
320853	A01 A30	B13 B40	C03 C06	43^b	351	3.98	ND	ND	ND	226^bc	141	4.58	4.67
321145	A11 A30	B13 B38	C06 C07	38^b	472	5.85	138^b	642	5.26	318^b	525	4.79	4.62
320019	A02 A30	B13 B46	C01 C06	46^b	163	4.46	58^bc	163	4.61	381^bc	411	4.77	4.50
321221	A11 A30	B13 B38	C06 C07	37^b	549	5.32	85	548	4.70	393^b	559	5.08	4.53
320088	A02 A11	B13 B13	C02 C03	53	ND	4.82	62^bc	330	4.07	327^bc	321	4.86	4.43
300471	A02 A30	B13 B35	C04 C06	134	269	4.23	139^b	262	4.23	360^bc	277	4.29	4.20
325020	A02 A24	B13 B40	C03 C08	ND	ND	ND	59^bc	638	3.29	309^bc	551	4.06	3.58
325029	A30 A30	B13 B13	C05 C06	27	429	5.40	83^b	572	4.46	337^b	573	3.10	3.59
320571	A02 A30	B13 B54	C01 C06	ND	ND	ND	131^c	353	4.71	335^c	373	4.63	4.50
320006	A02 A02	B13 B13	C03 C14	47	407	4.24	108^c	500	3.95	395	306	3.71	3.74
320135	A02 A32	B13 B44	C03 C04	46^b	685	3.77	63^bc	590	4.37	427^bc	564	3.75	3.75
440230	A02 A30	B13 B46	C01 C06	71	343	2.02	78^b	333	4.59	371^b	318	2.20	2.05

VL, viral load; dpi, days post-infection; ND, not detected
^a Average viral load (at least three time points) from 120 days to 1 year of infection
^b Deep-sequencing was undertaken at the indicated number of days post-HIV-1 infection
^c An interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay was performed for patients at the indicated number of days post-HIV-1 infection
^d Available samples at the time point closest to 3 months of HIV-1 infection

ISSN: 1471-2172